324 related articles for article (PubMed ID: 28432594)
1. MicroRNA Transfer Between Bone Marrow Adipose and Multiple Myeloma Cells.
Soley L; Falank C; Reagan MR
Curr Osteoporos Rep; 2017 Jun; 15(3):162-170. PubMed ID: 28432594
[TBL] [Abstract][Full Text] [Related]
2. Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.
Zhang L; Pan L; Xiang B; Zhu H; Wu Y; Chen M; Guan P; Zou X; Valencia CA; Dong B; Li J; Xie L; Ma H; Wang F; Dong T; Shuai X; Niu T; Liu T
Oncotarget; 2016 May; 7(21):30876-91. PubMed ID: 27129167
[TBL] [Abstract][Full Text] [Related]
3. The emerging role of exosomes in multiple myeloma.
Moloudizargari M; Abdollahi M; Asghari MH; Zimta AA; Neagoe IB; Nabavi SM
Blood Rev; 2019 Nov; 38():100595. PubMed ID: 31445775
[TBL] [Abstract][Full Text] [Related]
4. MicroRNAs and exosomes: Small molecules with big actions in multiple myeloma pathogenesis.
Pourhanifeh MH; Mahjoubin-Tehran M; Shafiee A; Hajighadimi S; Moradizarmehri S; Mirzaei H; Asemi Z
IUBMB Life; 2020 Mar; 72(3):314-333. PubMed ID: 31828868
[TBL] [Abstract][Full Text] [Related]
5. Promises and challenges of MicroRNA-based treatment of multiple myeloma.
Tagliaferri P; Rossi M; Di Martino MT; Amodio N; Leone E; Gulla A; Neri A; Tassone P
Curr Cancer Drug Targets; 2012 Sep; 12(7):838-46. PubMed ID: 22671926
[TBL] [Abstract][Full Text] [Related]
6. MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment.
Raimondi L; De Luca A; Morelli E; Giavaresi G; Tagliaferri P; Tassone P; Amodio N
Biomed Res Int; 2016; 2016():6504593. PubMed ID: 26881223
[TBL] [Abstract][Full Text] [Related]
7. Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.
Wang J; Faict S; Maes K; De Bruyne E; Van Valckenborgh E; Schots R; Vanderkerken K; Menu E
Oncotarget; 2016 Jun; 7(25):38927-38945. PubMed ID: 26950273
[TBL] [Abstract][Full Text] [Related]
8. Myeloma-Modified Adipocytes Exhibit Metabolic Dysfunction and a Senescence-Associated Secretory Phenotype.
Fairfield H; Dudakovic A; Khatib CM; Farrell M; Costa S; Falank C; Hinge M; Murphy CS; DeMambro V; Pettitt JA; Lary CW; Driscoll HE; McDonald MM; Kassem M; Rosen C; Andersen TL; van Wijnen AJ; Jafari A; Reagan MR
Cancer Res; 2021 Feb; 81(3):634-647. PubMed ID: 33218968
[TBL] [Abstract][Full Text] [Related]
9. Development of a 3D bone marrow adipose tissue model.
Fairfield H; Falank C; Farrell M; Vary C; Boucher JM; Driscoll H; Liaw L; Rosen CJ; Reagan MR
Bone; 2019 Jan; 118():77-88. PubMed ID: 29366838
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment.
Shay G; Tauro M; Loiodice F; Tortorella P; Sullivan DM; Hazlehurst LA; Lynch CC
Oncotarget; 2017 Jun; 8(26):41827-41840. PubMed ID: 28611279
[TBL] [Abstract][Full Text] [Related]
11. Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance.
Manni S; Carrino M; Semenzato G; Piazza F
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783691
[TBL] [Abstract][Full Text] [Related]
12. Microenvironment drug resistance in multiple myeloma: emerging new players.
Di Marzo L; Desantis V; Solimando AG; Ruggieri S; Annese T; Nico B; Fumarulo R; Vacca A; Frassanito MA
Oncotarget; 2016 Sep; 7(37):60698-60711. PubMed ID: 27474171
[TBL] [Abstract][Full Text] [Related]
13. Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.
Wang W; Corrigan-Cummins M; Barber EA; Saleh LM; Zingone A; Ghafoor A; Costello R; Zhang Y; Kurlander RJ; Korde N; Roccaro AM; Ghobrial IM; Landgren O; Calvo KR
J Mol Diagn; 2015 Nov; 17(6):669-78. PubMed ID: 26433312
[TBL] [Abstract][Full Text] [Related]
14. Adipose, Bone, and Myeloma: Contributions from the Microenvironment.
McDonald MM; Fairfield H; Falank C; Reagan MR
Calcif Tissue Int; 2017 May; 100(5):433-448. PubMed ID: 27343063
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of bone marrow adipose tissue in bone health and dysfunction.
Ambrosi TH; Schulz TJ
J Mol Med (Berl); 2017 Dec; 95(12):1291-1301. PubMed ID: 29101431
[TBL] [Abstract][Full Text] [Related]
16. NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma.
Yen CH; Hsiao HH
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30405034
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment.
Botta C; Cuce M; Caracciolo D; Fiorillo L; Tagliaferri P; Tassone P
Curr Cancer Drug Targets; 2017; 17(9):819-838. PubMed ID: 28359248
[TBL] [Abstract][Full Text] [Related]
18. Exosomal miRNAs in the Tumor Microenvironment of Multiple Myeloma.
Alipoor SD; Chang H
Cells; 2023 Mar; 12(7):. PubMed ID: 37048103
[TBL] [Abstract][Full Text] [Related]
19. The adipose organ and multiple myeloma: Impact of adipokines on tumor growth and potential sites for therapeutic intervention.
Allegra A; Innao V; Gerace D; Allegra AG; Vaddinelli D; Bianco O; Musolino C
Eur J Intern Med; 2018 Jul; 53():12-20. PubMed ID: 29859797
[TBL] [Abstract][Full Text] [Related]
20. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.
Besse L; Sedlarikova L; Kryukov F; Nekvindova J; Radova L; Slaby O; Kuglik P; Almasi M; Penka M; Krejci M; Adam Z; Pour L; Sevcikova S; Hajek R
PLoS One; 2015; 10(9):e0137294. PubMed ID: 26389804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
